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Abstract
Background: Tumor antigen (TA)–targeted monoclonal antibody (mAb) immunotherapy can be effective for the treatment
of a broad range of cancer etiologies; however, these approaches have demonstrated variable clinical efficacy for the
treatment of patients with prostate cancer (PCa). An obstacle currently impeding translational progress has been the
inability to quantify the mAb dose that reaches the tumor site and binds to the targeted TAs. The coupling of mAb to
nanoparticle-based magnetic resonance imaging (MRI) probes should permit in vivo measurement of patient-specific
biodistributions; these measurements could facilitate future development of novel dosimetry paradigms wherein mAb dose
is titrated to optimize outcomes for individual patients.
Methods: The prostate stem cell antigen (PSCA) is broadly expressed on the surface of prostate cancer (PCa) cells. Anti-
human PSCA monoclonal antibodies (mAb 7F5) were bound to Au/Fe3O4 (GoldMag) nanoparticles (mAb 7F5@GoldMag) to
serve as PSCA-specific theragnostic MRI probe permitting visualization of mAb biodistribution in vivo. First, the antibody
immobilization efficiency of the GoldMag particles and the efficacy for PSCA-specific binding was assessed. Next, PC-3
(prostate cancer with PSCA over-expression) and SMMC-7721 (hepatoma cells without PSCA expression) tumor-bearing
mice were injected with mAb 7F5@GoldMag for MRI. MRI probe biodistributions were assessed at increasing time intervals
post-infusion; therapy response was evaluated with serial tumor volume measurements.
Results: Targeted binding of the mAb 7F5@GoldMag probes to PC-3 cells was verified using optical images and MRI;
selective binding was not observed for SMMC-7721 tumors. The immunotherapeutic efficacy of the mAb 7F5@GoldMag in
PC-3 tumor-bearing mice was verified with significant inhibition of tumor growth compared to untreated control animals.
Conclusion: Our promising results suggest the feasibility of using mAb 7F5@GoldMag probes as a novel paradigm for the
detection and immunotherapeutic treatment of PCa. We optimistically anticipate that the approaches have the potential to
be translated into the clinical settings.
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Introduction
Prostate cancer (PCa) is the most common cancer among men
in the United States and is the second leading cause of death from
cancer in men [1]. Localized PCa can be treated with surgery or
radiation therapy, but the disease recurs in approximately 20 to
30% of patients. Androgen-deprivation therapy, the most common
treatment after recurrence, is effective, but the disease eventually
progresses in most patients who receive such treatment [2,3,4]. For
men with metastatic PCa, median survival in recent phase 3
studies ranged from 12.2 to 21.7 months [1,2,3,4]. A chemother-
apeutic agent, docetaxel, is the only approved therapy shown to
prolong survival among men with this condition, conferring a
median survival benefit of 2 to 3 months [5,6]. Conventional
anticancer therapies, such as chemotherapy and radiation therapy,
are characterized by a lack of tumor cell specificity.
Convincing evidence indicates that tumor antigen (TA)–
targeted monoclonal antibody (mAb)–based immunotherapy is
clinically effective for the treatment of a broad range of cancer
etiologies [7,8]. However, TA-targeted mAb-based immunother-
apy has demonstrated variable clinical efficacy for the treatment of
patients with PCa; this form of therapy has been effective in only a
subset of the disease expressing the specifically targeted TA [9,10].
An obstacle that is currently impeding translational progress has
been the inability to quantify the patient-specific dose of mAbs that
bind to the targeted TAs. This information remains largely
unknown in clinical settings but would permit patient-specific dose
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necessary (i.e. target a different antigen and/or utilize alternative
mAbs).
In clinical settings, 18-F fluorodeoxyglucose (FDG) positron
emission tomography (PET) provides an early and accurate way to
determine if cancer is responding to treatment. Some new
molecular imaging technologies with PET hold promise for PCa
management. Fluorestradiol (FES) measures estrogen receptors to
track tumors and fluorothymidine (FLT) provides insight into
cellular growth and proliferation [11,12]. More recently, there are
other metabolic PET tracers have been successfully tested for
prostate cancer [13,14]. Importantly, there has been a study that
used of humanized anti-PSCA (prostate stem cell antigen) intact
antibody as a molecular imaging probe for PET imaging, which is
currently under development for evaluation in a pilot clinical
imaging study [13]. However, PET may provide insufficient
spatial resolution for the detection of early stage of PCa [15]. The
advantages of MRI over nuclear-based molecular imaging
techniques include higher spatial resolution, superior soft tissue
contrast, and the ability to integrate molecular, anatomic, and
physiologic imaging data, all without exposing a patient to
potentially harmful radionuclides. In addition, MRI provides
insight into tumor function and has the potential to bridge further
the divide between molecular biology and clinical translation.
Recent pre-clinical research efforts to develop multi-modality
molecular imaging methods have the potential for noninvasive
PCa diagnosis and imaging-guided immunotherapy [16,17].
Multiple groups are actively pursuing the development of imaging
probes for cellular and molecular MRI [12,16,18,19,20]. Super-
paramagnetic iron oxide (SPIO) nanoparticles can be readily
bound to various molecular markers including ligands, antibodies,
and peptides as MRI probes [21,22,23,24]. The static magnetic
field is considerably disturbed by these SPIO-based probes, the
dephasing of the processing spins leads to localized signal loss in
MR images.
Au/Fe3O4 nanoparticles with a shell/core structure are
synthesized by reduction of Au
3+ with hydroxylamine in the
presence of Fe3O4 [25,26]. Au/Fe3O4 nanoparticles were used for
this study with an average size 50 nm (shell/core, 5/45 nm) in
diameter (GoldMag Biotechnology Co., Ltd, Xi’an). Magnetic
nanoparticles (Fe3O4) have attracted broad attention due to their
potential applications in MRI [21,22,23,24,27]. The formation of
gold shell on the magnetic nanoparticle was performed by an
iterative reduction method using hydroxylamine [28,29]. The
Fe3O4 core provides a particle of a small size with significant
magnetic moment, and a gold coating on the Fe3O4 core can
introduce a good platform for further conjugation with biomol-
ecules especially for biosensors fabrication. The gold-coated Fe3O4
nanoparticles were reported to exhibit good biocompatibility and
affinity via amine/thiol terminal groups [28,29]. With relative
larger antibody immobilization capacity, Au/Fe3O4 nanoparticles
are a good antibody carrier as compared with Au nanoparticles
and Fe3O4 nanoparticles. Because of inherent high saturation
magnetization, Au/Fe3O4 nanoparticles could response quickly to
extrinsic magnetic field with less time consumption during
separation process. Therefore, the gold-coated magnetic nanopar-
ticles satisfy the basic requirements as immunology carrier. These
Au/Fe3O4 nanoparticles require only a single step for antibody
immobilization and provide relatively large and stable antibody
binding capacities [20,26,30,31,32]. Antibody-conjugated Au/
Fe3O4 nanoparticles could potentially serve as a sensitive
theragnostic MRI probe permitting in vivo visualization of mAb
biodistribution and targeted delivery to tumors. These techniques
could ultimately allow clinicians to optimize individual dosage for
improved outcomes during immunotherapy and/or permit rapid,
timely adoption of alternate treatment strategies when needed.
The prostate stem cell antigen (PSCA) is a glycosyl phosphoi-
nositol–anchored cell surface protein that belongs to the Thy-1/
Ly-6 class of surface antigens. PSCA is an ideal candidate for the
development of reagents for the detection or immunotherapy of
PCa because it has increased expression specificity for PCa and
has a cell surface location [33,34,35,36]. mAb 7F5 is currently
recommended for the detection of PSCA of human origin during
Western Blotting, immunofluorescence and flow cytometry
procedures [36,37].
In this study, mAb 7F5 was conjugated to Au/Fe3O4
nanoparticles to produce novel MRI theragnostic probe (7F5@
Au/Fe3O4) for PCa. The purpose of the study was to investigate
the efficacy of this theragnostic MRI probe specifically targeting
PSCA on the surface of human prostate cancer cells (PC-3 cells)
for detection and immunotherapy in a mouse xenograft model.
Materials and Methods
Cell Lines and Animal Model
This study was conducted with the approval of the Institutional
Animal Care and Use Committee. All animals were housed and
handled according to the Institutional Animal Care and Use
Committee guidelines and all animal work was approved by the
appropriate committee (IACUC 0000000 and 0000000A-1). The
protocol was approved by the local Ethics committee (ethics
committee, Fourth Military Medical University 127/2008) and all
animals received humane care in compliance with ‘‘The Principles
of Laboratory Animal Care’’ formulated by the National Society
for Medical Research and the ‘‘Guide for the Care and Use of
Laboratory Animals’’ published by the National Institutes of
Health (NIH Publication No. 86–23, revised 1996).
Four to six-week-old nude mice (male Bab/c mice, weighing
between 25 and 30 g) were used for these studies. A human
prostate carcinoma cell line; the PC-3 was initiated from a bone
metastasis of a grade IV prostatic adenocarcinoma [33,34,35,36].
The cells were obtained commercially from American Type
Culture Collection (ATCC; Rockville, MD) and grown as a
monolayer in Eagle’s minimum essential medium (Invitrogen
Corp., Grand Island, New York) supplemented with 15% fetal
bovine serum (FBS) at 37uC under a mixture of 95% air and 5%
CO2. For creation of PC-3 tumor-bearing model, mouse was
inoculated with 2610
6 cells/5ml PBS in right flank. Another
tumor-bearing mouse (SMMC-7721 tumors without PSCA
expression) was created to serve as control group. SMMC-7721,
a human hepatoma carcinoma (HCC) cell line, was cultured in
Dulbecco’s modified Eagle medium (DMEM, Invitrogen Corp.,
Grand Island, New York) supplemented with 10% FBS at 37uC
under a mixture of 95% air and 5% CO2 [38].
Construction and Evaluation of mAb 7F5@Au/Fe3O4
Theragnostic MRI Probe
MRI theragnostic probes were constructed using either PCa
specific mAb 7F5 (Santa Cruz Biotechnology Inc., Santa Cruz,
California) or a non-specific antibody, mouse anti-human IgG
(Wuhan Boster Biology Co. Wuhan) to serve as a control probe.
Both 7F5@Au/Fe3O4 and IgG@Au/Fe3O4 probes were con-
structed as previously described [20,26,30,31,32]. Briefly, 200 ml
(1 mg/ml) of the Au/Fe3O4 nanoparticles were placed in a pipette
tube. This tube was then placed in a magnetic separator for 2 min.
100 mg of antibody protein (either mAb 7F5 or IgG) was dissolved
in 400 ml coupling buffer; the separated Au/Fe3O4 nanoparticles
were then added to 350 ml of the antibody solution. The remaining
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antibody solution with Au/Fe3O4 nanoparticles was placed in a
constant temperature (37uC) shaker for 20 min at 180 rpm, moved
to a centrifuge tube. This tube was placed in a magnetic separator
to remove the supernatant of immobilized antibody-Au/Fe3O4
nanoparticles. 50 ml of this supernatant was used for coupling
efficiency tests. The binding capacity of the Au/Fe3O4 surface was
determined using a UV2vis spectrophotometer (PerkinElmer,
Waltham, Massachusetts) and coupling efficiency (percentage of
protein uptake) calculated:
OD(Pre){OD(Post)
OD(Pre)
6100%, with
OD(pre) and OD(post) the absorbance measurements at 280 nm
for the 50 ml pre- and post-coupling antibody solutions, respec-
tively. Specific binding was evaluated previously described
[20,26,30,31,32]. In brief, separately, 5 mg/ml 7F5@Au/Fe3O4
or IgG@Au/Fe3O4 were incubated with 5610
5 PC-3 cells and
SMMC-7721 cells for 30 min in fluorescence-activated cell sorting
(FACS) buffer. The cells were washed twice with PBS, stained with
fluorescein isothiocyanate (FITC) conjugated goat anti-mouse
secondary antibody via incubation for 1.5 hrs (room temperature).
Samples were washed twice with PBS for the evaluation of specific
binding using flow cytometry assay. For optical microscopy
analysis, PC-3 and SMMC-7721 cells adhered to the coverslips.
Separately 200 mg/ml 7F5@Au/Fe3O4 or IgG@Au/Fe3O4 was
then incubated with PC-3 cells and SMMC-7721 cells for
overnight at 37uC. The cells were washed three times with PBS.
The cells were stained with Cy3 conjugated goat anti-mouse
secondary antibody via incubation for 1.5 hrs at room tempera-
ture. The cells were then fixed in 4% formalin for 30 min and
nuclear counterstaining was accomplished with 4, 6-diamidino-2-
phenylindole dihydrochloride (DAPI, Sigma, St. Louis, MO)
staining in a 1.5 mg/ml solution (5 min/RT). Finally, coverslips
were mounted and then visualized with laser scanning confocal
microscopy (LSCM, Olympus Optical Co. Ltd., Tokyo, Japan).
Toxicity of the 7F5@Au/Fe3O4 MRI Probe in Culturing PC-
3 Cells
PC-3 cells with 93%–95% viability (trypan blue staining) were
seeded in 96-well plates (4000 cells/well) with 4 ml culture
medium. The following day, 20 ml mAb 7F5 or 20 ml mAb 7F5@
GoldMag prob was added to PC-3 cell suspensions. In both cases,
the final concentration of mAb 7F5 was the same (0.2, 2, 4, 8 and
16 mg/ml, each n=6). The cells were treated with various mAb
7F5 concentrations (from mAb 7F5 solution or mAb 7F5@
GoldMag) in 96-well plates at cell culture incubator for 24 hrs.
The toxicity of equivalent amounts of GoldMag particles
compared to mAb 7F5@GoldMag was evaluated as well. The
final concentration of GoldMag particle was the same (2, 4, 8, 16,
and 32 mg/ml, each n=6). The cell viability (number of living
cells) was measured by trypan blue staining following treatment
24 hrs. The cell inhibition rate was calculated using the formula:
cell inhibition rate=(12 Npost/Npre)6100%; where Npost is the
number of living cells and Npre is the number of the cells in wells
pre-treated.
Toxicity of the 7F5@Au/Fe3O4 MRI Probe in Mice
Six-week-old nude mice (male Bb/c mice, weighing between 30
and 35 g, n=35) were used for the toxicity tests. All groups
received a single dose via intravenous injection. Three groups of
mice (each group n=5) received 7F5@ Au/Fe3O4; three groups
of mice (each group n=5) received IgG@Au/Fe3O4 at a doses of
100, 200 and 300 ml respectively (normalized dose 1 mg Au/
Fe3O4 with 50 mg antibody in each ml in following experiment).
Additional control group received saline injections (300 ml, n=5).
The toxicity of 7F5@Au/Fe3O4 or IgG@Au/Fe3O4 probes was
assessed with multiple indices. For acute toxicity, animals were
observed for events such as vital signs, mental, diet and activity
level following administration of the probe for 96 hrs. Systemic
toxicity was evaluated using the changes in animal body weights.
The weight and physical status of all the mice were monitored for
a period of 30 days. The animals were weighed on the day of
probe injection and every 5 days thereafter until 30 days post-
injection.
Magnetic Resonance Imaging
These studies were performed using a clinical 3.0T whole-body
MR-system (Siemens Magnetom Trio, Erlangen, Germany). The
system was capable of operating at a maximum slew rate of
200 mT/m/ms and a maximum gradient strength of 40 mT/m.
Integrated system body coils were used for RF excitation and an
eight-channel clinical head coil was used for signal reception.
In vitro MRI of 7F5@Au/Fe3O4 Targeted Cells
PC-3 cells and SMMC-7721 cells were cultured with 7F5@Au/
Fe3O4 and IgG@Au/Fe3O4 separately for 12 hrs. The concen-
trations of 7F5@Au/Fe3O4 and IgG@Au/Fe3O4 were 1 mg
Au/Fe3O4 per 50 mg antibody for each 1 ml of culture medium
with 0.5 million cells. After 12 hrs, harvested cells were washed 3
times with PBS. Cell samples were mixed with 1.5 ml 1% agarose
in small centrifuge tubes containing I) PC-3+7F5@Au/Fe3O4; II)
PC-3+ IgG@Au/Fe3O4; III) SMMC-7721+7F5@ Au/Fe3O4;o r
IV) SMMC-7721+ IgG@Au/Fe3O4 with each sample containing
roughly 5610
5 labeled cells (each group, n=8). Fast spin-echo T1-
weighted (T1w) and T2-weighted (T2w) MRI measurements were
performed using the following parameters: repetition time (TR)/
echo time (TE)=500/25 ms (T1w) and 4000/90 ms (T2w), field
of view (FOV)=1566156 mm
2; slice thickness=2 mm; matrix
size=1926192.
In vivo MRI of 7F5@Au/Fe3O4 Targeted Tumors
The PC-3 and SMMC-7721 tumor-bearing mice were injected
with either 200 ml (1 mg Au/Fe3O4 with 50 mg antibody in each
ml) 7F5@Au/Fe3O4 via tail vein (PC-3 tumor-bearing mice,
n=8; SMMC-7721 tumor-bearing mice, n=8) or 200 ml IgG@
Au/Fe3O4 (each, n=8). During MRI studies, mice were
anesthetized with ketamine (80 mg/kg) via intraperitoneal injec-
tion (IP). MRI studies were performed before and 6, 12, and
24 hrs post-injection. Following localization scout scans, FSE T1w
and T2w measurements were performed (T1w: TR/TE=500/
25 ms; T2w: TR/TE =4000/90 ms, slice thickness=3 mm,
FOV=56.256100 mm
2; slice thickness/slab thickness=2/
12.8 mm; matrix size=726128). After MRI, mice were eutha-
nized via CO2.
Assessment of 7F5@Au/Fe3O4 Probe Biodistribution
Tumor tissues were harvested from six mice following 7F5@
Au/Fe3O4 probe infusion (3 from each tumor-type) for histolog-
ical analysis. Tumor tissues were frozen in OCT medium and
sectioned at 5 mm intervals. For Prussian bluing staining, these
sections were incubated in a 1:1 solution of 10% aqueous solution
of potassium ferrocyanide and 20% hydrochloric acid for 30 min.
An additional 24 mice were used for quantitative analysis of
7F5@Au/Fe3O4 and IgG@Au/Fe3O4 probe distributions (4
groups, 6 mice/group having PC-3 or SMMC-7721 tumors and
receiving either the 7F5@Au/Fe3O4 and IgG@Au/Fe3O4 probe
infusions). Liver, spleen and tumor samples were collected from
each animal at 24 hrs post-injection. These tissues were prepared
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a CCD detector. (ICP-AES, Varian, Palo Alto, CA) by digesting
the cells with 25% chloric acid and then heating the solution until
a solid residue formed. The carbonaceous materials were removed
and the solid dissolved in 2% HNO3 (nitric acid). The
spectrometer detection wavelength was set to 238 nm for iron
and calibrated with three different standard samples (Fe selected as
the trace metal element for ICP-AES assessment of probe
distribution given that Fe is principle component of the Au/
Fe3O4 nanoparticles).
Anti-tumor Efficacy of Theragnostic Au/Fe3O4 MRI Probe
15 days after tumor cell implantation, 200 ml of the 7F5@Au/
Fe3O4 probe (PC-3 tumor-bearing mice, n=15; SMMC-7721
tumor-bearing mice, n=15) or 200 ml of the control IgG@Au/
Fe3O4 probe (PC-3 tumor-bearing mice, n=15; SMMC-7721
tumor-bearing mice, n=15) was injected via tail vein at days 0, 4,
and 8. Vital signs, mental status, diet and activity levels for each
animal were observed daily Tumor size was measured in three
dimensions (length, width, and height) with a caliper, and tumor
volume was calculated using the tumor volume formula =4/
3p6(length/2)6(width/2)6(height/2)[39]. The tumor volume was
measured at multiple time points following administration of the
probe (20, 25, 30, 35, 40, 45, 50, 55, 60 and 65 days after tumor
cell implantation, probe infusion on day 15). All mice were
euthanized at day 65.
Image Analysis and Statistical Methods
Image analyses were performed using ImageJ (version 1.34s,
National Institutes of Health, MD, USA). Region of interest (ROI)
were drawn encompassing cross-sections of respective vials or
mouse tumors (ROI included roughly 30 voxels for each phantom
vial, 30 voxels for each in vitro cell sample tube or 40 voxels for
each tumor) to measure mean T2w signal intensity (Smean).
Separate ROI were drawn outside of the tube or within a region
void of tissue (drawn at consistent positions between repeated
measurements) to estimate relative noise levels based upon the
standard deviation of the background signal (NSD). These
calculations were used to estimate the relative signal-to-noise ratio
(SNR) = Smean/NSD for each measurement. For tumor-bearing
mice, these measurements were repeated for each MRI scan post-
injection; these measurements were also repeated for each in vitro
Au/Fe3O4 cell sample vial.
All statistical calculations were performed using the SPSS
software package (SPSS, Chicago, IL, USA). For systemic toxicity
studies, to account for variability in baseline body weights, the time
course of body weight measurements for each animal were
reported as a percentage of the original baseline body weight.
One-way ANOVA was used to compare these adjusted body
weight indices across treatment groups at each time interval post-
infusion (Tukey post-hoc correction, p,0.05 considered statisti-
cally significant). Next, one-way ANOVA was used to compare a)
T2w SNR measurements from in vitro sample vials containing
different cell lines and targeting moieties and b) in vivo T2w SNR
measurements in tumors at pre-infusion and three post-infusion
time intervals (separate comparisons for PC-3 and SMMC-7221
mouse models). Similarly, one-way ANOVA was used to compare
organ-specific ICP-AES measurements of probe concentration in
PC-3 and SMMC-7721 tumor-bearing mice. Finally, for thera-
peutic efficacy studies, at each post-infusion observation interval, a
Student’s t-test was used to compare tumor volume measurements
between treated and control animals (p,0.05 considered statisti-
cally significant).
Results
Immobilization Efficiency and Specific Binding
Assessment
The rate of antibody-immobilized coupling was gradually
reduced with increasing concentrations of mAb 7F5. Adding
60 mg of mAb 7F5 to a 1 mg sample of Au/Fe3O4 nanoparticles
yielded a coupling efficiency close to 8369%; thus, for a 1 mg
sample, roughly 50 mg of the mAb 7F5 was surface-coupled to the
Au/Fe3O4 nanoparticles. To avoid biases during later in vitro and
in vivo comparison studies, coupling efficiency was also determined
for the non-specific antibody IgG. Under similar conditions, IgG
to Au/Fe3O4 nanoparticle coupling efficiency was approximately
7165% thus requiring the addition of 80 mg IgG protein to
achieve a surface-coupling of 50 mg IgG to corresponding 1 mg
sample of the Au/Fe3O4 nanoparticles. Flow cytometry demon-
strated that the positive rate of binding was 93.668.2% for the
7F5@Au/Fe3O4+ PC-3 cells, while the positive rate was only
4.261.2% for the 7F5@Au/Fe3O4+ SMMC-7721. The positive
rate of binding was 5.761.7% for IgG@Au/Fe3O4+ PC-3 cells
and 6.962.1% for IgG@Au/Fe3O4+ SMMC-7721 cells. Red
fluorescence was observed in the membrane and cytoplasm of the
7F5@Au/Fe3O4+ PC-3 cells with LSCM (top row in Fig. 1)
while no red fluorescence was observed in the 7F5@Au/Fe3O4+
SMMC-7721 cells (bottom row in Fig. 1). For the IgG@Au/
Fe3O4 group, no red fluorescence was observed for both PC-3
cells and SMMC-7721 cell lines.
Toxicity of the 7F5@GoldMag MRI Probe in Culturing PC-
3 Cells
Toxicity of the 7F5@GoldMag MRI Probe in vitro was shown
in Fig. S1. The toxicity of mAb 7F5 or 7F5@GoldMag was
demonstrated and the cell inhibition rate increased with increasing
mAb concentration; there is no statistical significance in each
concentration of mAb 7F5 or 7F5@GoldMag (p.0.05 in each
concentration, Fig. S1A). Moreover, when compared with 7F5@
GoldMag group, GoldMag particle alone did not affect cell
proliferation (p,0.05 in each concentration, Fig. S1B).
Toxicity of Theragnostic Au/Fe3O4 Probe in Mice
Acute toxicity: all mice survived and no abnormal reactions in
vital signs, mental status, diet, and activity levels 96hrs after
administration. Systemic toxicity in Fig. 2: mice in control group
gained weight steadily during the course of the experiment;
whereas weight gain was slightly reduced in animals receiving an
infusion of 7F5@Au/Fe3O4 at doses of both 100 mL and 200 mL.
No significant difference was observed between 7F5@Au/Fe3O4
and saline groups at any time point and none of these mice died
during the 30-day observation period post-infusion. No clinical
signs of toxicity such as trembling, decreased activity, or unstable
movements were observed. Similar results were observed for
IgG@Au/Fe3O4 treated animals at doses of 100 mL and 200 mL
(data not shown). However, from the 20-day observation interval
onward, those animals that received a 300 mL dose demonstrated
significantly lower body weights compared to those animals in
control and two lower dose groups (p,0.05 for each of these
normalized body weight gain comparisons). One mouse in this
high dose group died at day 30. Similar results were observed for
the high dose IgG@Au/Fe3O4 group with two of these mice
dying at days 25 and 27, respectively. Four mice from high dose
groups (three mice from 7F5@Au/Fe3O4 group and one from
IgG@Au/Fe3O4 group) showed clinical signs of toxicity including
trembling, decreased activity and unstable movements by day 20.
These results suggest increased systemic toxicity for those animals
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Fe3O4 probes.
In vitro MRI of 7F5@Au/Fe3O4 Targeted Cells
In vitro studies demonstrated significantly greater T2w SNR
reductions within PC-3+7F5@Au/Fe3O4 cell samples (tube I)
compared to the PC-3+ IgG@Au/Fe3O4 cell samples, SMMC-
7721+7F5@Au/Fe3O4 samples, and SMMC-7721+ IgG@Au/
Fe3O4 samples within tubes II, III, and IV respectively (Fig. 3A).
The samples within tubes II, III, and IV demonstrated no clearly
appreciable SNR reductions (comparisons yielded no statistically
significant differences from control, p.0.05 for each comparison);
the T2w SNR within PC-3+7F5@Au/Fe3O4 cell sample (tube I)
Figure 1. LSCM verifying specific targeting of 7F5@Au/Fe3O4 probe to PC-3 cells. Red fluorescence (7F5@Au/Fe3O4rpar; observed in the
membrane of the 7F5@Au/Fe3O4+ PC-3 cells (top row) while no red fluorescence was observed in the membrane of the 7F5@Au/Fe3O4+ SMMC-7721
cells (bottom row). Cell nuclei were stained blue in color via DAPI (middle column). 7F5@Au/Fe3O4 fluorescence images and DAPI images are merged
in right-most column. Scale bar, 10 mm.
doi:10.1371/journal.pone.0038350.g001
Figure 2. For systemic toxicity assessment, the time-coarse of animal weights were expressed as a percentage of individual
baseline weight; weight changes were compared for 100 mL, 200 mL and 300 mL dose groups and a saline control group.
doi:10.1371/journal.pone.0038350.g002
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III, and IV in Fig. 3B (p,0.05 for each comparison).
In vivo MRI of 7F5@Au/Fe3O4 Targeted Tumors
PC-3 tumor-bearing mice administered 7F5@Au/Fe3O4
nanoparticles demonstrated marked decreases in T2w tumor
signal intensity at 6, 12, and 24 hrs post-infusion (top row in
Fig. 4). No clearly appreciable tumor signal changes were
observed for SMMC -7721 tumor-bearing mice at any of the
three post-infusion time points (bottom row in Fig. 4). Histologic
analyses (Prussian blue staining in Fig. 4) showed heterogeneous
deposition of the Au/Fe3O4 Au/Fe3O4 nanoparticles depicted as
punctate blue-stained foci in the PC-3 tumor tissues; however,
these deposits were not observed within SMMC-7721 tumor
tissues.
Following 7F5@Au/Fe3O4 infusion, T2w SNR changes in PC-
3 tumors were statistically significant when compared to the
baseline pre-infusion tumor SNR levels (p,0.05 for each
comparison), Fig. 5A. Additional significant reductions in tumor
SNR were observed between the 6 and 12 hr post-infusion time
points (p,0.001); while mean T2w tumor SNR later increased
24 hrs post-infusion (relative to prior measurement at 12 hrs post-
infusion), this finding was not statistically significant given current
sample size (p=0.145). There were no statistically significant T2w
tumor SNR changes post-injection of 7F5@Au/Fe3O4 in mice
with SMMC -7721 tumors (p.0.05 for each comparison), Fig. 5B.
Assessment of 7F5@Au/Fe3O4 Probe Biodistribution
Fig. 6 shows the detected 7F5@Au/Fe3O4 and IgG@Au/
Fe3O4 probe levels in liver, spleen and tumor tissues for both PC-
3 tumor-bearing mice and SMMC-7721 tumor-bearing mice
based upon ICP measurements of Fe content 24 hrs post-injection.
These measurements reflect significant uptake of the Au/Fe3O4
probe given that endogenous Fe concentrations in murine liver
and splenic tissues are orders of magnitude lower than the Fe
concentrations observed for these same tissues. For both splenic
and liver tissues, Fe measurements 24 hrs post-infusion were
significantly higher in SMMC-7721 tumor-bearing mice and PC-3
mice following IgG@Au/Fe3O4 control probe injections com-
pared to these same tissues in PC-3 mice following 7F5@Au/
Fe3O4 injections (p,0.05 for each comparison). Conversely, Fe
measurements in tumor tissues demonstrated significantly higher
probe concentrations in PC-3 tumors following 7F5@Au/Fe3O4
injections compared PC-3 tumors after control probe injections
and SMMC-7721 tumors following injection of either targeted or
control probes.
Immunotherapeutic Efficacy of 7F5@Au/Fe3O4 Probe
Four groups of mice (7F5@Au/Fe3O4+ PC-3 tumor-bearing
mice; IgG@Au/Fe3O4+ PC-3 tumor-bearing mice; 7F5@Au/
Fe3O4+ SMMC-7721 tumor-bearing mice; IgG@Au/Fe3O4+
SMMC-7721 tumor-bearing mice) were administered a probe
dose of 200 ml at days 0, 4, and 8. The immunotherapeutic
efficacy of the 7F5@Au/Fe3O4 in PC-3 tumor-bearing mice was
verified with significant inhibition of tumor growth compared to
both untreated control animals and animals that received equal
doses of non-targeted IgG@Au/Fe3O4 probe, Fig. 7A. For PC-3
mice, at 40, 45, 50, 55, 60, and 65 day observation intervals post-
treatment, tumor volumes were significantly smaller for 7F5@Au/
Fe3O4 treated animals (p,0.05 for volume comparisons at each
of the four aforementioned intervals). No significant difference in
tumor volume progression was observed for SMMC-7721 mice
following injection of either 7F5@Au/Fe3O4 or IgG@Au/Fe3O4
probes, Fig. 7B.
Discussion
The refinement of molecular diagnostics and the integration of
these diagnostic capabilities with immunotherapy represent
important steps towards personalized medicine[40]. In this study,
a theragnostic MRI probe demonstrated the potential to serve a
dual role for diagnosis and immunotherapy in PCa. The imaging
and targeted therapy of PCa may be critical facets in effective
patient management for early disease detection and selective
treatment of malignant tissues. 7F5@Au/Fe3O4 theragnostic
probes selectively bound to PC-3 prostate tumors in the nude
mouse model. In vivo intravenous delivery of these probes was
readily visualized with conventional T2w MRI techniques using a
clinical scanner. These theragnostic probes lead to significant
inhibition of PC-3 tumor growth compared to control tumors
receiving equal doses of non-targeted IgG@Au/Fe3O4 probes.
The Au/Fe3O4 nanoparticles used for the current studies
possess both the optical properties of gold-colloid and the
Figure 3. In vitro MRI of 7F5@Au/Fe3O4 targeted cells. Tube I: PC-3+7F5@Au/Fe3O4 cell sample, tube II: PC-3+ IgG@Au/Fe3O4 sample; tube III:
SMMC-7721+7F5@Au/Fe3O4 sample; Tube IV: SMMC-7721+ IgG@Au/Fe3O4 sample. Quantitative T2w SNR measurements (B) for the cell sample vials
depicted in (A).
doi:10.1371/journal.pone.0038350.g003
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The latter feature produced strong T2w signal reduction
proportional to Au/Fe3O4 nanoparticle concentration during
our initial phantom studies. Goldmag nanoparticle with a size of
50 nm was used in our study because the core size (Fe3O4 with a
size of 45 nm indiameter) is similar to clinical approved Fe3O4
particle contract agents (FeridexH or Endorem
TM). We have
considerable experience in MRI tracking targeted cells in vivo.
Moreover, GoldMag nanoparticle with a size of 50 nm was
confirmed with higher antibody immobilization efficiency by
review of the related GoldMag literatures [20,25,26,30].
The process necessary to couple antibodies to the Au/Fe3O4
nanoparticlesisrelativelystraight-forwardrequiringonlycommonly
available laboratory equipment. Prior studies have demonstrated
thatthecouplingofIgGandIgMtoAu/Fe3O4nanoparticlesisstable
andhighlyefficient[20,30].Ourcurrentfindingswereconsistentwith
these prior studies.
No significant acute toxicities were observed in our mouse
models within 96 hrs following administration of the theragnostic
probe at dose levels of 100, 200 and 300 ml. At later time points
following a 300 ml dose, systemic toxicity was observed with
animals exhibiting weight loss, trembling, decreased activity, and
unstable movements for both 7F5@Au/Fe3O4 and IgG@Au/
Fe3O4 study groups. However, these observations were absent for
both 100 and 200 ml treatment groups. The latter finding served as
our rationale for using a 200 ml dose for subsequent study of the
Figure 4. MRI of 7F5@Au/Fe3O4 targeting tumor cells in vivo. PC-3 tumor-bearing mice administered 7F5@Au/Fe3O4 nanoparticles
demonstrated marked decreases in T2w tumor signal intensity 6, 12, and 24 hrs post-infusion (top row). No clearly appreciable tumor signal changes
were observed for SMMC -7721 tumor-bearing mice at any of the three post-infusion time points (bottom row). Prussian blue staining (PB) showed
that Au/Fe3O4 nanoparticles depicted as punctate blue-stained foci in the PC-3 tumor tissues; these deposits were not observed within SMMC-7721
tumor tissues. Scale bars, 10 mm for MRI and 50 mm for Prussian blue staining image.
doi:10.1371/journal.pone.0038350.g004
Figure 5. Quantitative T2w SNR measurements at 6, 12, and 24 hours post-infusion of 7F5@Au/Fe3O4 probe. T2w SNR changes (mean
6 SD) in PC-3 tumors were statistically significant at each time-point post-infusion when compared to the baseline pre-infusion tumor levels (p,0.05
for each comparison) (A). However, there were no statistically significant changes in T2w SNR for SMMC-7721 control tumors (B).
doi:10.1371/journal.pone.0038350.g005
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bearing mouse models.
PC-3 cells with over-expressing PSCA were targeted by the
7F5@Au/Fe3O4 nanoparticles for selective binding; these cells
were visualized as regions of significantly reduced signal intensity
within T2w MRI images. During subsequent in vivo studies, the
7F5@Au/Fe3O4 probe was administered intravenously to PC-3
tumor-bearing mice; at 6, 12, and 24 hrs intervals post-injection,
the T2w SNR within these tumors was significantly reduced
compared to pre-injection levels (greatest reduction observed at
12 hr post-injection interval). The evidence suggests the potential
to use 7F5@Au/Fe3O4 nanoparticles as in vivo MRI probes
specifically targeted to over PSCA expressing tumor cells.
ICP-AES studies to compare the biodistribution of 7F5@Au/
Fe3O4 and IgG@Au/Fe3O4 probes 24 hrs post-injection re-
vealed that the intra-tumoral uptake of the 7F5@Au/Fe3O4
probe was significantly superior (Fe concentration was 6-fold
greater than that in PC-3 tumors treated with IgG@Au/Fe3O4
probe) whereas the IgG@Au/Fe3O4 control probe tended to
accumulate in the liver and spleen. For non-targeted SMMC-7721
tumor model studies, both 7F5@Au/Fe3O4 and IgG@Au/
Fe3O4 probes tended to accumulate in the liver and spleen as
opposed to tumor tissues. These findings along with our in vivo
time-resolved MR imaging studies suggest that the mAb 7F5
targeting moiety played a key role in eliciting selective binding to
the targeted tumor cells during initial pharmacokinetic passage of
the probe to reduce reticuloendothelial system (RES) sequestration
within liver and splenic tissues.
Over a post-injection time-period of 50 days, significant growth
inhibition was achieved for PC-3 tumors treated with a 200 ml
dose, every 4 days repeated 3 times of the 7F5@Au/Fe3O4
probes. However, for SMMC-7721 tumor-bearing mice, no
Figure 6. Biodistribution of the probe in vivo measurements: The probes were assessed with ICP-AES measurements of Fe concentration
within liver, splenic, and tumor tissues for both PC-3 and SMMC-7721 mouse models.
doi:10.1371/journal.pone.0038350.g006
Figure 7. Evaluation of immunotherapeutic efficacy. For PC-3 mice, tumor volumes were significantly smaller for 7F5@Au/Fe3O4 treated
animals (p,0.05) compared to those mice with IgG@Au/Fe3O4 control probe (A). No significant difference in tumor volume progression was
observed for SMMC-7721 mice following injection of either 7F5@Au/Fe3O4 or IgG@Au/Fe3O4 probes (B).
doi:10.1371/journal.pone.0038350.g007
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inhibition of tumor growth was observed for tumors within either
PC-3 or SMMC-7721 tumor-bearing mice after injection of IgG@
Au/Fe3O4 control probe. The latter results suggest that the anti-
tumor efficacy of this theragnostic probe is the result of selective
binding of the mAb to the targeted PSCA antigen. Given the
demonstrable impact upon tumor growth, these probes may offer
important new treatment options for clinical patients with either
primary or metastatic PCa.
Our promising results suggest the feasibility of using 7F5@Au/
Fe3O4 probes as a novel paradigm for the detection and
immunotherapy of PCa. Clearly translational studies are necessary
to elucidate the sensitivity and specificity of these MRI methods for
detection and/or differential diagnoses of PCa in patients. We
optimistically anticipate that this theragnostic method has the
potential to be translated into the clinical environment given the
biocompatible gold-colloid iron-oxide composition of these
nanoparticles[20,30]. While the chosen synthesis reaction utilized
for the construction of these Au/Fe3O4 nanoparticles anticipated
being highly stable and reproducible; large-scale production
reproducibility for manufacturing clinically relevant human dose
volumes has yet to be rigorously evaluated. These factors will be
critical to address prior to future translational studies intended to
investigate the efficacy of these promising theragnostic PCa MRI
probes in patients.
Supporting Information
Figure S1 Toxicity of the 7F5@Au/Fe3O4 MRI Probe in
vitro. The toxicity of mAb 7F5 or 7F5@GoldMag was observed
and the cell inhibition rate increased with increasing mAb
concentration; there is no statistical significance in each concen-
tration of mAb 7F5 or 7F5@GoldMag (p.0.05 in each
concentration, Fig. S1A). Moreover, when compared with
7F5@GoldMag group, GoldMag particle alone did not affect cell
proliferation (p,0.05 in each concentration, Fig. S1B).
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